Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Highly Accessed Research article

Quality of life in purely ocular myasthenia in Japan

Shigeaki Suzuki1*, Hiroyuki Murai2, Tomihiro Imai3, Yuriko Nagane4, Masayuki Masuda5, Emiko Tsuda3, Shingo Konno6, Satoru Oji7, Shunya Nakane8, Masakatsu Motomura9, Norihiro Suzuki1 and Kimiaki Utsugisawa4

Author Affiliations

1 Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

2 Department of Neurology, Iizuka Hospital, Fukuoka, Japan

3 Department of Neurology, Sapporo Medical University, Hokkaido, Japan

4 Department of Neurology, Hanamaki General Hospital, Iwate, Japan

5 Department of Neurology, Tokyo Medical University, Tokyo, Japan

6 Department of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan

7 Department of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

8 Department of Neurology, Nagasaki Kawatana Medical Center, Nagasaki, Japan

9 Department of Clinical Neuroscience and Neurology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

For all author emails, please log on.

BMC Neurology 2014, 14:142  doi:10.1186/1471-2377-14-142

Published: 5 July 2014



Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, treatment guidelines were recently issued by the European Federation of Neurological Societies/European Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients with ocular myasthenia are not yet fully understood.


We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of the MG-QOL15, a self-appraised scoring system.


Of 607 myasthenia gravis (MG) patients with an observation-duration of illness ≥ 2 years, the cases of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with the patient’s QOL.


A treatment strategy designed in accord with a patient's ocular presentation must be considered in order to improve ocular symptoms and the patient's QOL.

Ocular myasthenia; Ocular-quantitative myasthenia gravis score; Quality-of-life; Therapeutic outcome